Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a buy rating to a strong-buy rating in a report released on Saturday.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.86.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $40.60 on Friday. The stock’s 50-day moving average is $36.56 and its two-hundred day moving average is $30.63. The stock has a market cap of $3.01 billion, a PE ratio of 1,015.25 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $40.89.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. On average, research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer owned 111,794 shares in the company, valued at $4,340,961.02. This represents a 46.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 12,368 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the sale, the chief operating officer owned 28,684 shares in the company, valued at $1,080,526.28. The trade was a 30.13% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 905,298 shares of company stock worth $32,343,574. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. Nuveen LLC acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $16,992,000. Arrowstreet Capital Limited Partnership acquired a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $20,349,000. Qube Research & Technologies Ltd raised its stake in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares in the last quarter. Acadian Asset Management LLC raised its stake in Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after buying an additional 651,700 shares in the last quarter. Finally, Rubric Capital Management LP raised its stake in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.